The primary rationale for assigning patients to the "other therapy" group included: the presence of genes associated with myelodysplastic syndrome (14), tp53 (5), RUNX1-RUNX1T1 (3), CBFB-MYH11 (1), cytogenetics indicating myelodysplastic changes (10), variant-type PML/RARA (1), MLL (1), and FLT3 (3). Here, TP53 is linked to myelodysplastic syndrome.